{"id":"W3169092451","doi":"10.1200/jco.2021.39.15_suppl.4565","title":"Ipilimumab + nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Nivolumab; Medicine; Ipilimumab; Renal cell carcinoma; Refractory (planetary science); Internal medicine; Oncology; Immunotherapy; Urology; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008033832,0.0002853729,0.0007014995,0.0002076972,0.0005158102,0.0003841485,0.0002805991,0.0004780017,0.001712062],"category_scores_gemma":[0.0006389737,0.0002210692,0.0008590635,0.0002897915,0.0002116106,0.0003658996,0.0004204489,0.0005628765,0.0003202977],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008983954,"about_ca_system_score_gemma":0.001216513,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003149912,"about_ca_topic_score_gemma":0.007044904,"domain_scores_codex":[0.9997674,0.00006354822,0.00002246349,0.00005353216,0.00002588858,0.00006732557],"domain_scores_gemma":[0.9997572,0.00002822304,0.00005334113,0.00001054796,0.00001414686,0.0001364421],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2376684,0.01716278,0.4168345,0.001586437,0.002156867,0.002270936,0.00199699,0.001077771,0.01896631,0.0003162834,0.006454969,0.2935078],"study_design_scores_gemma":[0.054818,0.2769418,0.6442552,0.0003274038,0.003182394,0.003052305,0.000844725,0.001666825,0.003951082,0.0003133423,0.0105901,0.00005685401],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977688,0.001044116,0.00004768768,0.0001066291,0.00001685994,0.000231985,0.0001324243,0.00001110362,0.000640523],"genre_scores_gemma":[0.9983359,0.0004520978,0.0001481245,0.0002391076,0.00003517815,0.0002315425,0.0002151764,0.000002301037,0.0003404993],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003149912,"threshold_uncertainty_score":0.006518304,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03373645546351024,"score_gpt":0.3276304910063669,"score_spread":0.2938940355428567,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}